Medvision Biomedicals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 4 Days
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.20 Cr
- Revenue Growth 8.36%
- Profit Growth 80.82%
- Ebitda 46.28%
- Net Worth 153.27%
- Total Assets 7.51%
About Medvision Biomedicals
Medvision Biomedicals Private Limited (MBPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 18 February 2019 (Six years 4 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.20 Cr.
Kishori Darade and Rajesh Darade serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U51909MH2019PTC321397
- Company No.
321397
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Feb 2019
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Medvision Biomedicals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kishori Darade  | Director | 18-Feb-2019 | Current |
| Rajesh Darade | Director | 18-Feb-2019 | Current |
Financial Performance of Medvision Biomedicals.
Medvision Biomedicals Private Limited, for the financial year ended 2021, experienced modest growth in revenue, with a 8.36% increase. The company also saw a substantial improvement in profitability, with a 80.82% increase in profit. The company's net worth Soared by an impressive increase of 153.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medvision Biomedicals?
In 2022, Medvision Biomedicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
One Pi Life Sciences LlpRajesh Darade is a mutual person
Charges (Loans)
₹12.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 1.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Sep 2019 | Others | ₹1.20 Cr | Open |
How Many Employees Work at Medvision Biomedicals?
Unlock and access historical data on people associated with Medvision Biomedicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medvision Biomedicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medvision Biomedicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.